Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 5, 2021

View Archived Issues

Immunome establishes partnership to advance IMM-BCP-01 for COVID-19

"Inceptor" is new diabetes target

Corvus initiates phase III study of CPI-006 hospitalized patients with COVID-19

4D pharma provides updates for its lead immune-oncology candidate, MRx-0518

New Aurora kinase inhibitors described by Wigen Biomedicine Technology

Abbisko Therapeutics identifies new PD-1/PD-L1 interaction inhibitors

Huaxiasheng Pharmaceutical patents AChE and NO production inhibitors

New NMT inhibitors discovered at CSPC Zhongqi Pharmaceutical Technology

Staidson (Beijing) Biopharmaceuticals patents antibodies targeting Pseudomonas PcrV

SSTR2 is highly expressed in thymic epithelial tumors

Positive preliminary phase I data for iNKT cell therapy in patients with COVID1-9

FDA clears IND application for INT-301 oral mucosal immunotherapy

Crinetics' lead candidate CRN-04894 enters phase I development

New research suggests COVID-19 antibodies persist at least 6 months

University of South Australia discovers new candidate for glioblastoma

Thapsigargin shows broad-spectrum activity against respiratory viruses including SARS-CoV-2

New U.K. trial explores alternating different COVID-19 vaccines

HIV and AMD

TQB-2450, alone or with anlotinib, shows safety and efficacy in previously-treated NSCLC

Zydus Cadila completes phase I trials with antimalarial ZY-19489

CEACAM7 is a therapeutic target for CART therapy in PDAC

Clinical study provides proof of principle for HIV vaccine candidate eOD-GT8 60mer

China NMPA approves phase III trial of orelabrutinib with R-CHOP for MCL

Phase II study of SHR-0302 in ulcerative colitis meets primary endpoint

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...